Details for Patent: 5,824,645

Title:	Method of treating inflammation
Abstract:	A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.
Inventor(s):	Justice; Alan (Sunnyvale, CA), Singh; Tejinder (Palo Alto, CA), Gohil; Kishor Chandra (Richmond, CA), Valentino; Karen L. (San Carlos, CA), Miljanich; George P. (Redwood City, CA)
Assignee:	Neurex Corporation (Menlo Park, CA)
Filing Date:	Nov 01, 1996
Application Number:	08/742,774
Claims:	1. A method of treating inflammation in a subject, in need of said treatment comprising administering to the subject a pharmacologically effective dose of an omega-conopeptide effective to (i) block voltage-gated calcium channels, (ii) bind with high affinity to an omega conopeptide binding site, and (iii) inhibit neurotransmitter release from nervous tissue. 2. The method of claim 1, wherein said effectiveness is within the range of activities measured for omega-conopeptides MVIIA/SNX-111, SNX-199, SNX-236, SNX-239 and TVIA/SNX-185. 3. The method of claim 1, wherein said neurotransmitter is norepinephrine. 4. The method of claim 1, wherein said omega-conopeptide is MVIIA. 5. A method of treating inflammation and associated pain in a subject, in need of said treatment comprising administering to the subject a pharmacologically effective dose of an omega-conopeptide effective to (i) block voltage-gated calcium channels, (ii) bind with high affinity to an omega conopeptide binding site, and (iii) inhibit neurotransmitter release from nervous tissue. 6. The method of claim 3, wherein said effectiveness in (i) blocking voltage-gated calcium channels, (ii) binding with high affinity to an omega conopeptide binding site, and (iii) inhibiting neurotransmitter release from nervous tissue is within the range of activities measured for omega-conopeptides MVIIA/SNX-111, SNX-199, SNX-236, SNX-239 and TVIA/SNX-185. 7. The method of claim 5, wherein said neurotransmitter release is norepinephrine release. 8. The method of claim 5, wherein said neurotransmitter release is acetylcholine release in a guinea pig ileum preparation. 9. The method of claim 5, wherein said omega-conopeptide is MVIIA.